A retrospective, observational study of survival data in subjects previously enrolled in celgene protocol CC-5013-MDS-003
Latest Information Update: 29 Sep 2022
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 29 Sep 2022 New trial record